General counsel of Sanofi
Appears in 1 story
Spoke publicly about Dupixent's patent portfolio in April 2026
Sanofi's biggest product is running out of room. Dupixent, the anti-inflammation antibody it co-developed with Regeneron, brought in $17.8 billion in 2025—roughly 36% of the French company's sales—and a key US patent expires in 2031.
Updated Yesterday
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
